{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:24:39Z","timestamp":1760016279331},"reference-count":57,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/internalmedicine.52.0023","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T23:03:12Z","timestamp":1384470192000},"page":"2577-2582","source":"Crossref","is-referenced-by-count":5,"title":["Ineffectiveness of Daptomycin in the Treatment of Septic Pulmonary Emboli and Persistent Bacteremia Caused by Methicillin-resistant <i>Staphylococcus aureus<\/i>"],"prefix":"10.2169","volume":"52","author":[{"given":"Hideharu","family":"Hagiya","sequence":"first","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"},{"name":"Emergency Unit and Critical Care Center, Tsuyama Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Hagioka","sequence":"additional","affiliation":[{"name":"Emergency Unit and Critical Care Center, Tsuyama Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 11: 30-38, 2011."},{"key":"2","unstructured":"2. Shorr AF, Tabak YP, Killian AD, et al. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med 34: 2588-2595, 2006."},{"key":"3","unstructured":"3. Turnidge JD, Kotsanas D, Munckhof W, et al. Australia New Zealand Cooperative on Outcomes in Staphylococcal Sepsis. Staphylococcus aureus<\/i> bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust 191: 368-373, 2009."},{"key":"4","unstructured":"4. Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to Staphylococcus aureus<\/i> bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol 24: 890-896, 2003."},{"key":"5","unstructured":"5. Fowler VG Jr, Boucher HW, Corey GR, S. aureus<\/i> Endocarditis and Bacteremia Study Group, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus<\/i>. N Engl J Med 355: 653-665, 2006."},{"key":"6","unstructured":"6. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus<\/i> bacteraemia: a meta-analysis. Med J Aust 175: 264-267, 2001."},{"key":"7","unstructured":"7. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus<\/i> bacteremia: a meta-analysis. Clin Infect Dis 36: 53-59, 2003."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Liu C, Bayer A, Cosgrove SE, Infectious Diseases Society of America, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus<\/i> infections in adults and children. Clin Infect Dis 52: e18-e55, 2011.","DOI":"10.1093\/cid\/ciq146"},{"key":"9","unstructured":"9. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus<\/i> infections: efficacy and toxicity. Arch Intern Med 166: 2138-2144, 2006."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus<\/i> bacteremia treated with vancomycin. Antimicrob Agents Chemother 52: 3315-3320, 2008.","DOI":"10.1128\/AAC.00113-08"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Maclayton DO, Suda KJ, Coval KA, York CB, Gtarey KW. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 mg\/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 28: 1208-1216, 2006.","DOI":"10.1016\/j.clinthera.2006.08.003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus<\/i> bacteremia. Clin Infect Dis 46: 193-200, 2008.","DOI":"10.1086\/524667"},{"key":"13","unstructured":"13. Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC. Nosocomial methicillin-resistant Staphylococcus aureus<\/i> (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC=2 mg\/L, by the broth microdilution method. BMC Infect Dis 10: 159, 2010."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Takesue Y, Nakajima K, Takahashi Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 mg\/ml methicillin-resistant Staphylococcus aureus<\/i> strains isolated from patients with bacteremia. J Infect Chemother 17: 52-57, 2011.","DOI":"10.1007\/s10156-010-0086-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus<\/i> bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 204: 340-347, 2011.","DOI":"10.1093\/infdis\/jir270"},{"key":"16","unstructured":"16. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus<\/i>: an antibiotic enters obsolescence. Clin Infect Dis 44: 1543-1548, 2007."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mohr JF, Murray BE. Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus<\/i>. Clin Infect Dis 44: 1536-1542, 2007.","DOI":"10.1086\/518451"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs 13: 1159-1169, 2004.","DOI":"10.1517\/13543784.13.9.1159"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus<\/i> peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 51: 1787-1794, 2007.","DOI":"10.1128\/AAC.00738-06"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus<\/i> on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48: 4665-4672, 2004.","DOI":"10.1128\/AAC.48.12.4665-4672.2004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38: 1673-1681, 2004.","DOI":"10.1086\/420818"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Gomez EO, Jafary A, Dever LL. Daptomycin and rifampin for the treatment of methicillin-resistant Staphylococcus aureus<\/i> septic pulmonary emboli in the absence of endocarditis. Microb Drug Resist 16: 241-244, 2010.","DOI":"10.1089\/mdr.2010.0001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus<\/i> Bacteremia. Clin Microbiol Rev 25: 362-386, 2012.","DOI":"10.1128\/CMR.05022-11"},{"key":"24","unstructured":"24. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus<\/i> bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 38: 7-14, 2006."},{"key":"25","unstructured":"25. Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. Persistent Staphylococcus aureus<\/i> bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 167: 1861-1867, 2007."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Liao CH, Chen SY, Huang YT, Hsueh PR. Outcome of patients with meticillin-resistant Staphylococcus aureus<\/i> bacteraemia at an Emergency Department of a medical centre in Taiwan. Int J Antimicrob Agents 32: 326-332, 2008.","DOI":"10.1016\/j.ijantimicag.2008.04.011"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ammerlaan H, Seifert H, Harbarth S, et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus<\/i> bacteremia in 9 Western European countries. Clin Infect Dis 49: 997-1005, 2009.","DOI":"10.1086\/605555"},{"key":"28","unstructured":"28. Fang CT, Shau WY, Hsueh PR, et al. Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus<\/i> bacteraemia: impact on the outcome. J Antimicrob Chemother 57: 511-519, 2006."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Soriano A, Martinez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus<\/i> bacteremia. Clin Infect Dis 30: 368-373, 2000.","DOI":"10.1086\/313650"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus<\/i> to daptomycin. J Clin Microbiol 44: 655-656, 2006.","DOI":"10.1128\/JCM.44.2.655-656.2006"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Hsu LY, Leong M, Balm M, et al. Six cases of daptomycin-non-susceptible Staphylococcus aureus<\/i> bacteraemia in Singapore. J Med Microbiol 59: 1509-1513, 2010.","DOI":"10.1099\/jmm.0.022533-0"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus<\/i> bacteremia. Clin Infect Dis 40: 1058-1060, 2005.","DOI":"10.1086\/428616"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus<\/i> isolate during treatment of methicillin-resistant Staphylococcus aureus<\/i> bacteremia and osteomyelitis. J Clin Microbiol 44: 595-597, 2006.","DOI":"10.1128\/JCM.44.2.595-597.2006"},{"key":"34","unstructured":"34. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus<\/i> bacteraemia in a daptomycin-naïve patient: a review of the literature. Eur J Clin Microbiol Infect Dis 30: 603-610, 2011."},{"key":"35","unstructured":"35. Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int J Antimicrob Agents 30: 143-149, 2007."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus<\/i> by exposure to vancomycin. Antimicrob Agents Chemother 50: 1581-1585, 2006.","DOI":"10.1128\/AAC.50.4.1581-1585.2006"},{"key":"37","unstructured":"37. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus<\/i>: facts and assumptions. Lancet Infect Dis 9: 617-624, 2009."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus<\/i>. Clin Infect Dis 42: 1652-1653, 2006.","DOI":"10.1086\/504084"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Boyle-Vavra S, Jones M, Gourley BL, et al. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus<\/i> isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother 55: 2018-2025, 2011.","DOI":"10.1128\/AAC.01593-10"},{"key":"40","unstructured":"40. Steenbergen JN, Mohr JF, Thorne GM. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 64: 1130-1138, 2009."},{"key":"41","unstructured":"41. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191: 2149-2152, 2005."},{"key":"42","unstructured":"42. Griffith GL, Maull KI, Sachatello CR. Septic pulmonary embolization. Surg Gynecol Obstet 144: 105-108, 1977."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. O'Donnell AE, Selig J, Aravamuthan M, Richardson MS. Pulmonary complications associated with illicit drug use. An update. Chest 108: 460-463, 1995.","DOI":"10.1378\/chest.108.2.460"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Jaffe RB, Koschmann EB. Septic pulmonary emboli. Radiology 96: 527-532, 1970.","DOI":"10.1148\/96.3.527"},{"key":"45","unstructured":"45. Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation 95: 2098-2107, 1997."},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 348: 1123-1133, 2003.","DOI":"10.1056\/NEJMra011883"},{"key":"47","unstructured":"47. Lee SJ, Cha SI, Kim CH, et al. Septic pulmonary embolism in Korea: microbiology, clinicoradiologic features, and treatment outcome. J Infect 54: 230-234, 2007."},{"key":"48","unstructured":"48. Sinave CP, Hardy GJ, Fardy PW. The Lemierre syndrome: suppurative thrombophlebitis of the internal jugular vein secondary to oropharyngeal infection. Medicine (Baltimore) 68: 85, 1989."},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Golpe R, Marin B, Alonso M. Lemierre's syndrome (necrobacillosis). Postgrad Med J 75: 141, 1999.","DOI":"10.1136\/pgmj.75.881.141"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Otten TR, Stein PD, Patel KC, Mustafa S, Silbergleit A. Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 123: 809-812, 2003.","DOI":"10.1378\/chest.123.3.809"},{"key":"51","unstructured":"51. Cook RJ, Ashton RW, Aughenbaugh GL, Ryu JH. Septic pulmonary embolism: presenting features and clinical course of 14 patients. Chest 128: 162-166, 2005."},{"key":"52","unstructured":"52. Fowler VG. Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus<\/i> bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 27: 478-486, 1998."},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Jenkins TC, Price CS, Sabel AL, Mehler PS, Burman WJ. Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus<\/i> bacteremia. Clin Infect Dis 46: 1000-1008, 2008.","DOI":"10.1086\/529190"},{"key":"54","unstructured":"54. Kaech C, Elzi L, Sendi P, et al. Course and outcome of Staphylococcus aureus<\/i> bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect 12: 345-352, 2006."},{"key":"55","unstructured":"55. Mylotte JM, Tayara A. Staphylococcus aureus<\/i> bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis 31: 1170-1174, 2000."},{"key":"56","unstructured":"56. Rieg S, Peyerl-Hoffmann G, de With K, et al. Mortality of S. aureus<\/i> bacteremia and infectious diseases specialist consultation: a study of 521 patients in Germany. J Infect 59: 232-239, 2009."},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Paul M, Kariv G, Goldberg E. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus<\/i> bacteraemia. J Antimicrob Chemother 65: 2658-2665, 2010.","DOI":"10.1093\/jac\/dkq373"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/22\/52_52.0023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:46:12Z","timestamp":1621446372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/22\/52_52.0023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":57,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.52.0023","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}